PUBLISHER: 360iResearch | PRODUCT CODE: 1592037

PUBLISHER: 360iResearch | PRODUCT CODE: 1592037

Kaposi Sarcoma Market by Type (Classic Kaposi Sarcoma, Endemic Kaposi Sarcoma, Epidemic Kaposi Sarcoma), Drug Class (Doxil, Doxorubicin Hydrochloride Liposome, Intron A ), Treatment, Mode of Treatment - Global Forecast 2025-2030

PUBLISHED: October 31, 2024

PAGES: 189 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The Kaposi Sarcoma Market was valued at USD 140.29 million in 2023, expected to reach USD 145.55 million in 2024, and is projected to grow at a CAGR of 3.73%, to USD 181.40 million by 2030.

Kaposi Sarcoma is a cancer that forms in the lining of blood and lymph vessels and typically appears on the skin or mucosal surfaces. The necessity and application scope in this market center around the urgent need for advanced diagnostics, effective therapeutics, and personalized treatments, especially given its prevalence among immunocompromised patients, such as those with HIV/AIDS. The end-use market predominantly includes hospitals, research institutes, and specialty clinics that focus on oncology and virology. Market growth is driven by the increasing global cancer burden, advancements in molecular biology, and the growing awareness and advocacy around rare diseases. Key influencing factors include the prevalence of HIV, improvements in early detection methods, and governmental and non-governmental support initiatives. Notably, collaborations between biotech companies and research institutions offer lucrative opportunities for breakthroughs in treatment modalities and drug discoveries. However, the market is challenged by the high costs of research and development, potential side effects of treatment, and a need for greater access to comprehensive healthcare, particularly in developing regions. Additionally, limited awareness and understanding of Kaposi Sarcoma in the general population contribute to late-stage diagnoses, compounding treatment challenges. Promising areas of innovation include targeted therapies, immunotherapies, and the integration of AI in diagnostics to improve early detection rates. Research on Kaposi Sarcoma-associated herpes virus (KSHV) offers potential for preventive strategies and novel therapeutic approaches. The nature of the market is highly specialized, requiring ongoing cross-disciplinary collaborations among oncologists, virologists, and pharmacologists. Recommendations for capturing market opportunities involve investing in cutting-edge research, fostering partnerships between public and private sectors, and enhancing patient education and outreach programs to ensure early diagnosis and adherence to treatment regimens. Despite the market complexities, there lies tremendous potential for impactful innovations that can improve patient outcomes globally.

KEY MARKET STATISTICS
Base Year [2023]	USD 140.29 million
Estimated Year [2024]	USD 145.55 million
Forecast Year [2030]	USD 181.40 million
CAGR (%)	3.73%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Kaposi Sarcoma Market

The Kaposi Sarcoma Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Increasing prevalence of HIV-associated Kaposi Sarcoma
- Rising number of patients undergoing organ transplantation procedures
- Growing number of clinical studies related to Kaposi Sarcoma disease
Market Restraints
- High cost associated with diagnosis of Kaposi Sarcoma treatment
Market Opportunities
- Investment in R&D activities for Kaposi Sarcoma treatment
- Introduction of advanced highly active antiretroviral treatment
Market Challenges
- Lack of skilled workforce and shortage in the supply of drugs

Porter's Five Forces: A Strategic Tool for Navigating the Kaposi Sarcoma Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Kaposi Sarcoma Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Kaposi Sarcoma Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Kaposi Sarcoma Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Kaposi Sarcoma Market

A detailed market share analysis in the Kaposi Sarcoma Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Kaposi Sarcoma Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Kaposi Sarcoma Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Kaposi Sarcoma Market

A strategic analysis of the Kaposi Sarcoma Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Kaposi Sarcoma Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amneal Pharmaceuticals LLC, Aphios Corporation, Aurobindo Pharma Limited, Bausch Health Companies Inc., Baxter International, Inc., Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Cipla Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, Getwell Oncology Pvt Ltd, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, John Wiley & Sons, Inc., Johnson & Johnson Services, Inc, Lupin Ltd., Merck & Co., Inc, Mylan N.V., Navidea Biopharmaceuticals, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Kaposi Sarcoma Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Type, market is studied across Classic (Mediterranean) Kaposi Sarcoma, Endemic (African) Kaposi Sarcoma, Epidemic (AIDS-associated) Kaposi Sarcoma, and Iatrogenic (Transplant-Related) Kaposi Sarcoma.
Based on Drug Class, market is studied across Doxil (Doxorubicin Hydrochloride Liposome), Doxorubicin Hydrochloride Liposome, Intron A (Recombinant Interferon Alfa-2b), Paclitaxel, Pomalidomide, Pomalyst (Pomalidomide), Recombinant Interferon Alfa-2b, and Vinblastine Sulfate.
Based on Treatment, market is studied across Biological Therapy, Chemotherapy, Cryosurgery, HAART, Radiation Therapy, Surgery, and Treatment.
Based on Mode of Treatment, market is studied across Chemotherapy and Intralesional Injection.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-C002B1C994FA

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing prevalence of HIV-associated Kaposi Sarcoma
  - 5.1.1.2. Rising number of patients undergoing organ transplantation procedures
  - 5.1.1.3. Growing number of clinical studies related to Kaposi Sarcoma disease
- 5.1.2. Restraints
  - 5.1.2.1. High cost associated with diagnosis of Kaposi Sarcoma treatment
- 5.1.3. Opportunities
  - 5.1.3.1. Investment in R&D activities for Kaposi Sarcoma treatment
  - 5.1.3.2. Introduction of advanced highly active antiretroviral treatment
- 5.1.4. Challenges
  - 5.1.4.1. Lack of skilled workforce and shortage in the supply of drugs
5.2. Market Segmentation Analysis
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Kaposi Sarcoma Market, by Type

6.1. Introduction
6.2. Classic (Mediterranean) Kaposi Sarcoma
6.3. Endemic (African) Kaposi Sarcoma
6.4. Epidemic (AIDS-associated) Kaposi Sarcoma
6.5. Iatrogenic (Transplant-Related) Kaposi Sarcoma

7. Kaposi Sarcoma Market, by Drug Class

7.1. Introduction
7.2. Doxil (Doxorubicin Hydrochloride Liposome)
7.3. Doxorubicin Hydrochloride Liposome
7.4. Intron A (Recombinant Interferon Alfa-2b)
7.5. Paclitaxel
7.6. Pomalidomide
7.7. Pomalyst (Pomalidomide)
7.8. Recombinant Interferon Alfa-2b
7.9. Vinblastine Sulfate

8. Kaposi Sarcoma Market, by Treatment

8.1. Introduction
8.2. Biological Therapy
8.3. Chemotherapy
8.4. Cryosurgery
8.5. HAART
8.6. Radiation Therapy
8.7. Surgery
8.8. Treatment

9. Kaposi Sarcoma Market, by Mode of Treatment

9.1. Introduction
9.2. Chemotherapy
9.3. Intralesional Injection

10. Americas Kaposi Sarcoma Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Kaposi Sarcoma Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Kaposi Sarcoma Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation

Companies Mentioned

1. Abbott Laboratories
2. AbbVie Inc.
3. Amneal Pharmaceuticals LLC
4. Aphios Corporation
5. Aurobindo Pharma Limited
6. Bausch Health Companies Inc.
7. Baxter International, Inc.
8. Bayer AG
9. Bristol-Myers Squibb Company
10. Celgene Corporation
11. Cipla Limited
12. Eli Lilly and Company
13. F. Hoffmann-La Roche AG
14. Getwell Oncology Pvt Ltd
15. GlaxoSmithKline PLC
16. Hikma Pharmaceuticals PLC
17. John Wiley & Sons, Inc.
18. Johnson & Johnson Services, Inc
19. Lupin Ltd.
20. Merck & Co., Inc
21. Mylan N.V.
22. Navidea Biopharmaceuticals, Inc.
23. Pfizer Inc.
24. Sun Pharmaceutical Industries Ltd.
25. Teva Pharmaceutical Industries Ltd.

Product Code: MRR-C002B1C994FA

LIST OF FIGURES

FIGURE 1. KAPOSI SARCOMA MARKET RESEARCH PROCESS
FIGURE 2. KAPOSI SARCOMA MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL KAPOSI SARCOMA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 9. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 11. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2023 VS 2030 (%)
FIGURE 13. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. KAPOSI SARCOMA MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. KAPOSI SARCOMA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

TABLE 1. KAPOSI SARCOMA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL KAPOSI SARCOMA MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. KAPOSI SARCOMA MARKET DYNAMICS
TABLE 7. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CLASSIC (MEDITERRANEAN) KAPOSI SARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY ENDEMIC (AFRICAN) KAPOSI SARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY EPIDEMIC (AIDS-ASSOCIATED) KAPOSI SARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY IATROGENIC (TRANSPLANT-RELATED) KAPOSI SARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DOXIL (DOXORUBICIN HYDROCHLORIDE LIPOSOME), BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DOXORUBICIN HYDROCHLORIDE LIPOSOME, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY INTRON A (RECOMBINANT INTERFERON ALFA-2B), BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY PACLITAXEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY POMALIDOMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY POMALYST (POMALIDOMIDE), BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY RECOMBINANT INTERFERON ALFA-2B, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY VINBLASTINE SULFATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY BIOLOGICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CRYOSURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY HAART, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY INTRALESIONAL INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 45. CANADA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 46. CANADA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 47. CANADA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 48. CANADA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 49. MEXICO KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 50. MEXICO KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. MEXICO KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 52. MEXICO KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 63. AUSTRALIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. AUSTRALIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 65. AUSTRALIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 67. CHINA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 68. CHINA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 69. CHINA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 70. CHINA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 71. INDIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 72. INDIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 73. INDIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 74. INDIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 75. INDONESIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76. INDONESIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 77. INDONESIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 78. INDONESIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 79. JAPAN KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80. JAPAN KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 81. JAPAN KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 82. JAPAN KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 83. MALAYSIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 84. MALAYSIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 85. MALAYSIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 86. MALAYSIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 87. PHILIPPINES KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 88. PHILIPPINES KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 89. PHILIPPINES KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 90. PHILIPPINES KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 91. SINGAPORE KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 92. SINGAPORE KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 93. SINGAPORE KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 94. SINGAPORE KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 95. SOUTH KOREA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 96. SOUTH KOREA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 97. SOUTH KOREA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 98. SOUTH KOREA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 99. TAIWAN KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 100. TAIWAN KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 101. TAIWAN KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 102. TAIWAN KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 103. THAILAND KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 104. THAILAND KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 105. THAILAND KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 106. THAILAND KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 107. VIETNAM KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 108. VIETNAM KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 109. VIETNAM KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 110. VIETNAM KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 116. DENMARK KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 117. DENMARK KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 118. DENMARK KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 119. DENMARK KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 120. EGYPT KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 121. EGYPT KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. EGYPT KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 123. EGYPT KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 124. FINLAND KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 125. FINLAND KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. FINLAND KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 127. FINLAND KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 128. FRANCE KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 129. FRANCE KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 130. FRANCE KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 131. FRANCE KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 132. GERMANY KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 133. GERMANY KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. GERMANY KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 135. GERMANY KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 136. ISRAEL KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. ISRAEL KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 138. ISRAEL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 139. ISRAEL KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 140. ITALY KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 141. ITALY KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 142. ITALY KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 143. ITALY KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 144. NETHERLANDS KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 145. NETHERLANDS KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 146. NETHERLANDS KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 147. NETHERLANDS KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 148. NIGERIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 149. NIGERIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 150. NIGERIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 151. NIGERIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 152. NORWAY KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 153. NORWAY KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 154. NORWAY KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 155. NORWAY KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 156. POLAND KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 157. POLAND KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 158. POLAND KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 159. POLAND KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 160. QATAR KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 161. QATAR KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 162. QATAR KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 163. QATAR KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 166. RUSSIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 167. RUSSIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 168. SAUDI ARABIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 170. SAUDI ARABIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 172. SOUTH AFRICA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 173. SOUTH AFRICA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 174. SOUTH AFRICA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 175. SOUTH AFRICA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 176. SPAIN KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 177. SPAIN KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 178. SPAIN KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 179. SPAIN KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 182. SWEDEN KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 183. SWEDEN KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 184. SWITZERLAND KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 185. SWITZERLAND KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 186. SWITZERLAND KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 187. SWITZERLAND KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 188. TURKEY KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 189. TURKEY KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 190. TURKEY KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 191. TURKEY KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 196. UNITED KINGDOM KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 198. UNITED KINGDOM KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
TABLE 200. KAPOSI SARCOMA MARKET SHARE, BY KEY PLAYER, 2023
TABLE 201. KAPOSI SARCOMA MARKET, FPNV POSITIONING MATRIX, 2023

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ